Clinical Trial Update: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) [Phase 3]

View source ↗

Summary

Phase 3 randomized trial of eculizumab in AQP4 antibody-positive neuromyelitis optica spectrum disorder was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Status: TERMINATED | Results posted: 2019-06-26